SOMAÍ Pharmaceuticals

SOMAÍ Pharmaceuticals Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoi

d-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

SOMAÍ today announced the signing of an exclusive partnership agreement with IPS Pharma and Integro Medical Clinics to i...
27/05/2026

SOMAÍ today announced the signing of an exclusive partnership agreement with IPS Pharma and Integro Medical Clinics to introduce a portfolio of internationally recognized cannabis brands into the United Kingdom medical cannabis market.

The agreement covers the future launch of three globally recognized cannabis brands into the UK medical market in the coming months, representing a significant expansion of differentiated cannabinoid product offerings available to UK healthcare professionals and patients.

“The UK market is continuing to mature rapidly, and new patient demographics are increasingly looking for differentiated products backed by advanced pharmaceutical-grade producers,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “This partnership creates a strong foundation for introducing some of the industry’s most recognized international brands with unique genetic portfolios into the UK medical market.”

“At IPS Pharma and Integro Clinics, our focus has always been on improving patient access to safe, compliant, and high-quality cannabinoid medicines,” said Ashok Patel, Founder and Chairman of IPS Pharma. “Working together with SOMAÍ allows us to support the introduction of globally recognized brands through a structured and patient-focused approach.”

Read the full news here: https://www.einpresswire.com/article/915255345/soma-signs-exclusive-uk-agreement-to-launch-globally-recognized-cannabis-brands

🔵 SOMAÍ at CannaTrade 2026 🇨🇭The SOMAÍ team will be attending CannaTrade 2026 in Zurich from May 29–31, connecting with ...
25/05/2026

🔵 SOMAÍ at CannaTrade 2026 🇨🇭

The SOMAÍ team will be attending CannaTrade 2026 in Zurich from May 29–31, connecting with healthcare professionals, distributors, pharmacies, and industry partners across the Swiss market.

Rachel Wilson-Cannon, Commercial Director at SOMAÍ, will be on-site and available to discuss SOMAÍ’s expanding portfolio of EU-GMP cannabinoid-based medicines, including extracts, upcoming products, and differentiated international brands.

Interested in learning more about SOMAÍ’s product offerings and opportunities in Switzerland?
Reach out to schedule a meeting: hello@somaipharma.eu

🔵 Thailand’s cannabis industry is entering a new phase 🌏In his latest article for CannaReporter, Michael Sassano explore...
22/05/2026

🔵 Thailand’s cannabis industry is entering a new phase 🌏

In his latest article for CannaReporter, Michael Sassano explores the rapid evolution of the Thai cannabis market — from explosive cultivation growth and pricing pressure to the increasing importance of pharmaceutical standards and international market access.

As global demand for compliant cannabis products continues to rise, Thailand is quickly becoming one of the most closely watched regions in the industry.

🔷 The article explores:
• The expansion of Thailand’s indoor cultivation sector
• The challenges of meeting global pharmaceutical standards
• Pricing pressure and oversupply dynamics
• The growing role of EU-GMP pathways in international distribution

Read the full article here: https://cannareporter.eu/en/2026/04/30/canabis-na-tailandia-em-2026-de-suave-a-selvagem/

🔵 SOMAÍ Shortlisted for Three Business of Cannabis Awards 2026 🌐We’re proud to share that SOMAÍ has been shortlisted in ...
18/05/2026

🔵 SOMAÍ Shortlisted for Three Business of Cannabis Awards 2026 🌐

We’re proud to share that SOMAÍ has been shortlisted in three categories at the Business of Cannabis Awards 2026:

🏆 Producer of the Year — SOMAÍ
🏆 European Company of the Year — SOMAÍ
🏆 Industry Rising Star Award — Rachel Wilson-Cannon

These nominations reflect the dedication of our global team and our continued focus on advancing EU-GMP cannabinoid-based medicines through innovation, quality, and international collaboration.

🩵 A special congratulations to Rachel Wilson-Cannon for this well-deserved recognition of her contribution to the industry and SOMAÍ’s global growth.

💙 Thank you to the Business of Cannabis Awards team, our partners, and everyone supporting SOMAÍ’s journey.

🔵 SOMAÍ at Cannabiz Awards 2026 (AU & NZ) 🌏We’re pleased to share that Michael Sassano, Founder and Interim CEO of SOMAÍ...
13/05/2026

🔵 SOMAÍ at Cannabiz Awards 2026 (AU & NZ) 🌏

We’re pleased to share that Michael Sassano, Founder and Interim CEO of SOMAÍ, has been selected as a judge for the Cannabiz Awards for Australia and New Zealand 2026.

The awards recognise excellence across the medical cannabis sector, celebrating achievements in innovation, manufacturing, patient care, technology, leadership, and industry collaboration.

This year’s edition introduces new categories and one of the largest judging panels to date, reflecting the continued growth and maturity of the Australian and New Zealand medical cannabis markets.

SOMAÍ looks forward to supporting the recognition of companies and individuals helping shape the future of regulated cannabinoid medicines.

🔷 Learn more about the awards: https://www.cannabiz.com.au/cannabizawards2026/

🔵 SOMAÍ Hybrid 100 now available in Germany 🇩🇪Expanding our EU-GMP extract portfolio, SOMAÍ introduces a high-THC formul...
05/05/2026

🔵 SOMAÍ Hybrid 100 now available in Germany 🇩🇪

Expanding our EU-GMP extract portfolio, SOMAÍ introduces a high-THC formulation designed for consistency, reliability, and compliance.

Supporting healthcare professionals with standardized cannabinoid therapies across regulated markets.

Get in touch to learn more: info@somaipharma.de

As SOMAÍ continues to expand globally, Sassano is visiting key markets this May to strengthen partnerships and support ...
04/05/2026

As SOMAÍ continues to expand globally, Sassano is visiting key markets this May to strengthen partnerships and support local operations.

Want to connect with Michael and the team? Reach out: hello@somaipharma.eu

28/04/2026

Inside SOMAÍ Cultivation with Dr. Nigel Gale 🔹

Why do we take cuttings from the very top of the plant?

This is where plant science, consistency, and careful cultivation practice come together. In this episode, Dr. Nigel Gale explains how top cuttings support the development of strong new plants, helping preserve the genetic blueprint and quality potential of each cultivar.

At SOMAÍ and NovaSoma, every step in cultivation is guided by precision, care, and a deep understanding of the plant.

More from our cultivation series coming soon. 💙

CannabisScience CultivationExcellence MedicalCannabisEducation

28/04/2026

Inside SOMAÍ Cultivation with Dr. Nigel Gale 🔹

Why do we take cuttings from the very top of the plant?

Because this is where plant science, consistency, and careful cultivation practice come together. In this episode, Dr. Nigel Gale explains how top cuttings support the development of strong new plants, helping preserve the genetic blueprint and quality potential of each cultivar.

At SOMAÍ and NovaSoma, every step in cultivation is guided by precision, care, and a deep understanding of the plant.

More from our cultivation series coming soon. 💙

For two decades, the fight to acknowledge cannabis as a legitimate medicine in the USA has stumbled through a lobbying a...
27/04/2026

For two decades, the fight to acknowledge cannabis as a legitimate medicine in the USA has stumbled through a lobbying and bureaucratic minefield. But the landscape has shifted permanently. While recent Trump executive actions don’t fully “legalize” the plant recreationally, they send a thunderous message: the FDA will officially acknowledge cannabis as a medicine.

As regulatory frameworks evolve across multiple markets, companies are being pushed to operate with the same rigor as traditional pharmaceutical systems — from cultivation through to final product release.

A new article by Michael Sassano published in Ignite IT highlights a key shift in the industry: the move toward EU-GMP-driven medical cannabis supply chains and global standardisation.

Explore the full article and key insights: https://www.igniteit.com/news/boom-the-age-of-eu-gmp-medical-cannabis-is-here-the-global-race-is-on/

23/04/2026

🔵 ICBC 2026 — Thank You 🌐

Thank you to everyone who connected with the SOMAÍ team at .

From insightful conversations to new partnerships, it was a great few days discussing the future of medical cannabis.

We look forward to continuing the conversations — see you next year.

Address

Brisbane, QLD

Website

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Shortcuts

Featured

Share

Category